Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.64 |
| ▸ | ITGAV | P06756 | 20/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366048 | 1.00 | ITGB3 (0.64) | ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL3366046 | 0.99 | ITGB3 (0.64) | ITGB3ITGAVITGA2B | |
| Acetic Acid SCHEMBL3369129 | 0.98 | ITGB3 (0.64) | ITGB3ITGAVITGA2B | |
| SCHEMBL3368836 | 0.92 | ITGB3 (0.76) | ITGB3ITGAVITGA2B | |
| SCHEMBL7138885 | 0.92 | ITGB3 (0.76) | ITGB3ITGAVITGA2B | |
| SCHEMBL3370168 | 0.91 | ITGB3 (0.64) | ITGB3ITGAVITGA2B | |
| SCHEMBL6016329 | 0.87 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL6016326 | 0.87 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL3366589 | 0.81 | ITGB3 (0.45) | ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL3366043 | 0.81 | ITGB3 (0.44) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867213-B2 | (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-15 | — | — | US | claimed |
| US-20040039006-A1 | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039006-A1 | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | CALCRL, CALCR, CHRNA1 | ITGB3 153/4885ITGAV 223/4885ITGA2B 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.